502:
475:
605:
617:
512:
336:
315:
163:
429:
404:
702:
22:
74:
53:
84:
660:
751:
If there is other other fair use media, consider checking that you have specified the fair use rationale on the other images used on this page. Note that any fair use images uploaded after 4 May, 2006, and lacking such an explanation will be deleted one week after they have been uploaded, as
818:
181:
284:
748:
is an easy way to insure that your image is in compliance with
Knowledge policy, but remember that you must complete the template. Do not simply insert a blank template on an image page.
542:
828:
635:
833:
823:
559:
813:
595:
585:
798:
386:
376:
838:
808:
549:
220:
207:
803:
793:
630:
485:
140:
729:, you must also write out on the image description page a specific explanation or rationale for why using this image in each article is consistent with
783:
554:
130:
788:
726:
352:
753:
745:
741:
718:
778:
194:
106:
757:
525:
480:
214:
678:
537:
343:
320:
435:
409:
97:
58:
690:
275:
533:
on
Knowledge. If you would like to participate, please visit the project page, where you can join the ongoing discussions.
188:
175:
33:
201:
737:
709:
21:
622:
672:
247:
227:
39:
517:
440:
414:
713:
is being used on this article. I notice the image page specifies that the image is being used under
761:
351:
on
Knowledge. If you would like to participate, please visit the project page, where you can join
105:
on
Knowledge. If you would like to participate, please visit the project page, where you can join
714:
687:
501:
474:
668:
233:
89:
264:
604:
240:
162:
701:
772:
682:
530:
335:
314:
730:
348:
428:
403:
612:
507:
79:
529:, a collaborative effort to improve the coverage of topics relating to the
102:
73:
52:
764:
695:
15:
182:
Knowledge:Requested articles/Business and economics/Companies
700:
603:
725:
Knowledge article constitutes fair use. In addition to the
819:
Start-Class United States articles of Low-importance
347:, a collaborative effort to improve the coverage of
101:, a collaborative effort to improve the coverage of
756:. If you have any questions please ask them at the
653:Fair use rationale for Image:Peoplesdruglogo.PNG
438:, a project which is currently considered to be
8:
829:Low-importance District of Columbia articles
221:Category:Company articles needing infoboxes
208:Category:Company articles needing attention
19:
469:
398:
309:
170:Here are some tasks awaiting attention:
148:
47:
834:WikiProject District of Columbia articles
824:Start-Class District of Columbia articles
471:
400:
311:
49:
746:Knowledge:Fair use rationale guideline
814:Low-importance United States articles
246:Help expand stub articles located at
7:
799:Low-importance pharmacology articles
523:This article is within the scope of
434:This article is within the scope of
341:This article is within the scope of
195:Category:Unassessed company articles
95:This article is within the scope of
570:Knowledge:WikiProject United States
38:It is of interest to the following
839:WikiProject United States articles
809:Start-Class United States articles
573:Template:WikiProject United States
361:Knowledge:WikiProject Pharmacology
14:
804:WikiProject Pharmacology articles
794:Start-Class pharmacology articles
364:Template:WikiProject Pharmacology
744:. Using one of the templates at
658:
631:WikiProject District of Columbia
615:
510:
500:
473:
427:
402:
334:
313:
272:Tag company talk pages with the
161:
82:
72:
51:
20:
784:Low-importance company articles
590:This article has been rated as
450:Knowledge:WikiProject Retailing
381:This article has been rated as
135:This article has been rated as
115:Knowledge:WikiProject Companies
789:WikiProject Companies articles
758:Media copyright questions page
453:Template:WikiProject Retailing
261:Tag company articles with the
118:Template:WikiProject Companies
1:
727:boilerplate fair use template
628:This article is supported by
355:and see a list of open tasks.
109:and see a list of open tasks.
779:Start-Class company articles
754:criteria for speedy deletion
152:WikiProject Companies To-do:
855:
738:the image description page
656:
596:project's importance scale
387:project's importance scale
141:project's importance scale
740:and edit it to include a
710:Image:Peoplesdruglogo.PNG
696:06:09, 14 June 2007 (UTC)
611:
589:
526:WikiProject United States
495:
422:
380:
329:
147:
134:
67:
46:
765:06:38, 6 June 2007 (UTC)
719:explanation or rationale
531:United States of America
344:WikiProject Pharmacology
623:Washington, D.C. portal
705:
608:
576:United States articles
248:Category:Company stubs
28:This article is rated
721:as to why its use in
704:
607:
436:WikiProject Retailing
367:pharmacology articles
285:requests for comments
276:WikiProject Companies
98:WikiProject Companies
518:United States portal
486:District of Columbia
544:Articles Requested!
742:fair use rationale
706:
609:
456:Retailing articles
34:content assessment
694:
667:Taken care of by
650:
649:
646:
645:
642:
641:
468:
467:
464:
463:
397:
396:
393:
392:
308:
307:
304:
303:
300:
299:
296:
295:
846:
717:but there is no
698:
685:
662:
661:
625:
620:
619:
618:
578:
577:
574:
571:
568:
520:
515:
514:
513:
504:
497:
496:
491:
488:
477:
470:
458:
457:
454:
451:
448:
431:
424:
423:
418:
406:
399:
369:
368:
365:
362:
359:
338:
331:
330:
325:
317:
310:
279:
268:
234:Portal:Companies
176:Article requests
165:
158:
157:
149:
123:
122:
121:company articles
119:
116:
113:
92:
90:Companies portal
87:
86:
85:
76:
69:
68:
63:
55:
48:
31:
25:
24:
16:
854:
853:
849:
848:
847:
845:
844:
843:
769:
768:
699:
681:). Thank you! —
666:
664:
659:
655:
621:
616:
614:
575:
572:
569:
566:
565:
564:
550:Become a Member
516:
511:
509:
489:
483:
455:
452:
449:
446:
445:
412:
366:
363:
360:
357:
356:
323:
292:
289:
273:
262:
120:
117:
114:
111:
110:
88:
83:
81:
61:
32:on Knowledge's
29:
12:
11:
5:
852:
850:
842:
841:
836:
831:
826:
821:
816:
811:
806:
801:
796:
791:
786:
781:
771:
770:
762:BetacommandBot
657:
654:
651:
648:
647:
644:
643:
640:
639:
636:Low-importance
627:
626:
610:
600:
599:
592:Low-importance
588:
582:
581:
579:
563:
562:
557:
552:
547:
540:
538:Template Usage
534:
522:
521:
505:
493:
492:
490:Low‑importance
478:
466:
465:
462:
461:
459:
432:
420:
419:
407:
395:
394:
391:
390:
383:Low-importance
379:
373:
372:
370:
353:the discussion
339:
327:
326:
324:Low‑importance
318:
306:
305:
302:
301:
298:
297:
294:
293:
291:
290:
288:
287:
281:
280:project banner
270:
258:
250:
236:
223:
210:
197:
184:
169:
167:
166:
154:
153:
145:
144:
137:Low-importance
133:
127:
126:
124:
107:the discussion
94:
93:
77:
65:
64:
62:Low‑importance
56:
44:
43:
37:
26:
13:
10:
9:
6:
4:
3:
2:
851:
840:
837:
835:
832:
830:
827:
825:
822:
820:
817:
815:
812:
810:
807:
805:
802:
800:
797:
795:
792:
790:
787:
785:
782:
780:
777:
776:
774:
767:
766:
763:
759:
755:
752:described on
749:
747:
743:
739:
736:Please go to
734:
732:
728:
724:
720:
716:
712:
711:
703:
697:
692:
689:
684:
680:
677:
674:
670:
652:
637:
634:(assessed as
633:
632:
624:
613:
606:
602:
601:
597:
593:
587:
584:
583:
580:
567:United States
561:
558:
556:
553:
551:
548:
546:
545:
541:
539:
536:
535:
532:
528:
527:
519:
508:
506:
503:
499:
498:
494:
487:
482:
481:United States
479:
476:
472:
460:
443:
442:
437:
433:
430:
426:
425:
421:
416:
411:
408:
405:
401:
388:
384:
378:
375:
374:
371:
354:
350:
346:
345:
340:
337:
333:
332:
328:
322:
319:
316:
312:
286:
282:
277:
271:
266:
260:
259:
257:
255:
251:
249:
245:
243:
242:
237:
235:
232:
230:
229:
224:
222:
219:
217:
216:
211:
209:
206:
204:
203:
198:
196:
193:
191:
190:
185:
183:
180:
178:
177:
172:
171:
168:
164:
160:
159:
156:
155:
151:
150:
146:
142:
138:
132:
129:
128:
125:
108:
104:
100:
99:
91:
80:
78:
75:
71:
70:
66:
60:
57:
54:
50:
45:
41:
35:
27:
23:
18:
17:
760:. Thank you.
750:
735:
722:
708:
707:
675:
669:Caldorwards4
629:
591:
555:Project Talk
543:
524:
439:
382:
358:Pharmacology
349:Pharmacology
342:
321:Pharmacology
267:|Companies}}
253:
252:
239:
238:
226:
225:
213:
212:
200:
199:
187:
186:
174:
173:
136:
96:
40:WikiProjects
30:Start-class
773:Categories
447:Retailing
410:Retailing
112:Companies
103:companies
59:Companies
731:fair use
715:fair use
691:contribs
683:Elipongo
679:contribs
663:Resolved
441:inactive
415:inactive
269:template
228:Maintain
202:Copyedit
594:on the
385:on the
283:Answer
215:Infobox
139:on the
560:Alerts
265:portal
189:Assess
36:scale.
254:Other
241:Stubs
723:this
688:Talk
673:talk
586:Low
377:Low
131:Low
775::
733:.
665:–
638:).
484::
278:}}
274:{{
263:{{
693:)
686:(
676:·
671:(
598:.
444:.
417:)
413:(
389:.
256::
244::
231::
218::
205::
192::
179::
143:.
42::
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
